These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline]. Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP; Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. Calleja JL; Pascasio JM; Ruiz-Antorán B; Gea F; Bárcena R; Larrubia JR; Pérez-Álvarez R; Sousa JM; Romero-Gómez M; Solá R; de la Revilla J; Crespo J; Navarro JM; Arenas JI; Delgado M; Fernández-Rodríguez CM; Planas R; Buti M; Forns X; Liver Int; 2015 Jan; 35(1):90-100. PubMed ID: 25113158 [TBL] [Abstract][Full Text] [Related]
6. [Not Available]. Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M Orv Hetil; 2015 Dec; 156 Suppl 2():3-24. PubMed ID: 26667111 [TBL] [Abstract][Full Text] [Related]
7. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA]. Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553 [TBL] [Abstract][Full Text] [Related]
9. [Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 15 October 2016]. Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M Orv Hetil; 2017 Feb; 158(Suppl 1):3-22. PubMed ID: 28218867 [TBL] [Abstract][Full Text] [Related]
10. Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers. Sukeepaisarnjaroen W; Pham T; Tanwandee T; Nazareth S; Galhenage S; Mollison L; Totten L; Wigg A; Altus R; Colman A; Morales B; Mason S; Jones T; Leembruggen N; Fragomelli V; Sendall C; Guan R; Sutedja D; Tan SS; Dan YY; Lee YM; Luman W; Teo EK; Than YM; Piratvisuth T; Lim SG World J Gastroenterol; 2015 Jul; 21(28):8660-9. PubMed ID: 26229408 [TBL] [Abstract][Full Text] [Related]
11. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP; J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289 [TBL] [Abstract][Full Text] [Related]
12. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study. Stasi C; Piluso A; Arena U; Salomoni E; Montalto P; Monti M; Boldrini B; Corti G; Marra F; Laffi G; Milani S; Zignego AL World J Gastroenterol; 2015 Mar; 21(10):3013-9. PubMed ID: 25780300 [TBL] [Abstract][Full Text] [Related]
14. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Verna EC; Saxena V; Burton JR; O'Leary JG; Dodge JL; Stravitz RT; Levitsky J; Trotter JF; Everson GT; Brown RS; Terrault NA; Transplantation; 2015 Aug; 99(8):1644-51. PubMed ID: 25715116 [TBL] [Abstract][Full Text] [Related]
15. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1. Manns MP; Markova AA; Calle Serrano B; Cornberg M Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568 [TBL] [Abstract][Full Text] [Related]
16. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. Vierling JM; Davis M; Flamm S; Gordon SC; Lawitz E; Yoshida EM; Galati J; Luketic V; McCone J; Jacobson I; Marcellin P; Muir AJ; Poordad F; Pedicone LD; Albrecht J; Brass C; Howe AY; Colvard LY; Helmond FA; Deng W; Treitel M; Wahl J; Bronowicki JP J Hepatol; 2014 Apr; 60(4):748-56. PubMed ID: 24362076 [TBL] [Abstract][Full Text] [Related]
17. [Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis]. Makara M; Horváth G; Gervain J; Pár A; Szalay F; Telegdy L; Tornai I; Ujhelyi E; Hunyady B Orv Hetil; 2012 Mar; 153(10):375-94. PubMed ID: 22370225 [TBL] [Abstract][Full Text] [Related]
18. [Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 22 September 2017]. Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M Orv Hetil; 2018 Feb; 159(Suppl 1):3-23. PubMed ID: 29478339 [TBL] [Abstract][Full Text] [Related]
19. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. Bruno S; Vierling JM; Esteban R; Nyberg LM; Tanno H; Goodman Z; Poordad F; Bacon B; Gottesdiener K; Pedicone LD; Albrecht JK; Brass CA; Thompson S; Burroughs MH J Hepatol; 2013 Mar; 58(3):479-87. PubMed ID: 23183529 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]